Clinical Laboratory of Emergency Medicine, Tianjin Union Medical Centre, Tianjin, China.
Graduate School of Tianjin Medical University, Tianjin, China.
Int J Med Sci. 2021 Jan 21;18(6):1356-1362. doi: 10.7150/ijms.53564. eCollection 2021.
Cytokine release syndrome (CRS) may be the key factor in the pathology of severe coronavirus disease 2019 (COVID-19). As a major driver in triggering CRS in patients with COVID-19, interleukin-6 (IL-6) appears to be a promising target for therapeutics. The results of inhibiting both trans- and classical- signaling with marketed IL-6 inhibitors (tocilizumab, siltuximab and sarilumab) in severe COVID-19 patients are effective based on several small studies and case reports thus far. In this review, we described the evidence of the IL-6 response in patients with COVID-19, clarified the pathogenesis of the role of IL-6-mediated CRS in severe COVID-19, and highlighted the rationale for the use of anti-IL-6 agents and key information regarding the potential features of these IL-6 inhibitors in COVID-19 patients.
细胞因子释放综合征（CRS）可能是严重 2019 冠状病毒病（COVID-19）病理学的关键因素。白细胞介素-6（IL-6）作为引发 COVID-19 患者 CRS 的主要驱动因素，似乎是治疗的一个有前途的靶点。迄今为止，几项小型研究和病例报告表明，用市售的 IL-6 抑制剂（托珠单抗、西妥昔单抗和沙利鲁单抗）抑制转导和经典信号对重症 COVID-19 患者有效。在这篇综述中，我们描述了 COVID-19 患者中 IL-6 反应的证据，阐明了 IL-6 介导的 CRS 在严重 COVID-19 中的发病机制，并强调了使用抗 IL-6 药物的基本原理以及这些 IL-6 抑制剂在 COVID-19 患者中的潜在特征的关键信息。
